Droxidopa

Structural formula
General
Surname	Droxidopa
other names	L - threo -3,4-dihydroxyphenylserine L- threo-DOPS L -DOPS (2 S , 3 R ) -2-amino-3- (3,4-dihydroxyphenyl) -3-hydroxypropanoic acid
Molecular formula	C 9 H 11 NO 5
External identifiers / databases
CAS number 23651-95-8 EC number 688-528-3 ECHA InfoCard 100.215.254 PubChem 92974 ChemSpider 83927 DrugBank DB06262 Wikidata Q907853
Drug information
Mechanism of action	Norepinephrine precursor
properties
Molar mass	213.19 g mol −1
safety instructions
GHS labeling of hazardous substances Caution H and P phrases H: 315-319-335 P: ?
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Droxidopa is a prodrug against Parkinson's disease that is metabolized when it crosses the blood-brain barrier to produce the messenger substance norepinephrine . Droxidopa can make up for a lack of norepinephrine in the brain .

Areas of application are the so-called freezing symptom (freezing of movement), dopamine-β-hydroxylase deficiency and orthostatic circulatory regulation disorders .

The active ingredient was synthesized for the first time in 1919 in the laboratories of Sumitomo Pharmaceuticals , back then as a racemate . The drug has been available on the Japanese market under the trade name DOPS since 1989. Since 2005, Chelsea Therapeutics (now Lundbeck ) has been trying to obtain approval from the Food and Drug Administration for droxidopa as a treatment for orthostatic hypotension . In 2007 Droxidopa was declared an orphan drug . In February 2014, the substance was finally approved in the USA as Northera .

See also

• Catecholamines

literature

• David S. Goldstein: L-Dihydroxyphenylserine (L-DOPS). A norepinephrine prodrug. In: Cardiovascular Drug Reviews . Vol. 24, No. 3/4, pp. 189-203, doi : 10.1111 / j.1527-3466.2006.00189.x .

Individual evidence

1. ↑ There is not yet a harmonized classification for this substance . A labeling of (2S, 3R) -2-Amino-3- (3,4-dihydroxyphenyl) -3-hydroxypropanoic acid in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on 16 December 2020.
2. ↑ Chelsea gains Orphan Drug status for Droxidopa . Reuters report of January 22, 2007.
3. ^ Pharmaceutical newspaper: Droxidopa approved , February 24, 2014

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !